Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | MGAM | O43451 | 1/20 | 0.48 |
| ▸ | SI | P14410 | 1/20 | 0.48 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12784068 | 0.87 | CYP1A2 (0.55) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL2397581 | 0.84 | SMN1; SMN2 (0.49) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL11806061 | 0.84 | GAA (0.50) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL28390346 | 0.83 | DGKA (0.45) | SMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL18037948 | 0.82 | SMN1; SMN2 (0.50) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL1556696 | 0.82 | SMN1; SMN2 (0.50) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL2991444 | 0.81 | CYP1A2 (0.44) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL11025207 | 0.81 | CYP1A2 (0.44) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL17827615 | 0.81 | ALDH1A1 (0.47) | CYP1A2SMN1; SMN2POLBALDH1A1ALOX15 | |
| SCHEMBL2982758 | 0.80 | CYP1A2 (0.47) | CYP1A2GAAMGAMSIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108199035-B | Lithium secondary battery | 麦克赛尔控股株式会社 | 2021-05-28 | — | — | CN | disclosed |
| CN-111066192-A | Nonaqueous electrolyte secondary battery | 三菱化学株式会社 | 2020-04-24 | — | — | CN | disclosed |
| EP-2237358-B1 | Nonaqueous electrolyte battery | MITSUBISHI CHEM CORP (JP) | 2015-08-12 | — | — | EP | disclosed |
| US-8962192-B2 | Nonaqueous electrolytic solution and nonaqueous electrolyte battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2015-02-24 | — | — | US | disclosed |
| US-8574757-B2 | Nonaqueous electrolytic solution and nonaqueous electrolyte battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2013-11-05 | — | — | US | disclosed |
| EP-2128923-B1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY | MITSUBISHI CHEM CORP (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-20120264011-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-10-18 | — | — | US | disclosed |
| US-20120156557-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-06-21 | — | — | US | disclosed |
| US-8153647-B2 | Aryl- and heteroaryl-ethyl-acylguanidine derivatives, their preparation and their application in therapeutics | SANOFI-AVENTIS (FR) | 2012-04-10 | — | — | US | disclosed |
| EP-2237358-A1 | Nonaqueous electrolyte battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2010-10-06 | — | — | EP | disclosed |
| US-20100035147-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2010-02-11 | — | — | US | disclosed |
| EP-2128923-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY | Mitsubishi Chemical Corporation (JP) | 2009-12-02 | — | — | EP | disclosed |
| US-20090203696-A1 | Aryl- and Heteroaryl-Ethyl-Acylguanidine Derivatives, Their Preparation and Their Application in Therapeutics | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203696-A1 | Aryl- and Heteroaryl-Ethyl-Acylguanidine Derivatives, Their Preparation and Their Application in Therapeutics | RAB9A, UGT1A9, CD59 | CYP1A2 280/4885GAA 35/4885MGAM 2073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.